Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and
metastasis of colorectal cancer
#MMPMID30015842
Zhang H
; Yang W
; Yan J
; Zhou K
; Wan B
; Shi P
; Chen Y
; He S
; Li D
Int J Oncol
2018[Sep]; 53
(3
): 1118-1128
PMID30015842
show ga
Profilin 2 (PFN2) functions as an actin cytoskeleton regulator and serves an
important role in cell motility. However, a role for PFN2 in the progression of
colorectal cancer (CRC), particularly in metastasis, has yet to be clarified. The
aim of the present study was to investigate whether PFN2 served specific roles in
the progression of human CRC. The results demonstrated that PFN2 was
differentially expressed in CRC tissues and cell lines by reverse
transcription-quantitative polymerase chain reaction and western blotting. PFN2
expression was also negatively associated with the degree of tumor metastasis.
Low PFN2 expression in CRC cells was related with enhanced epithelial-mesenchymal
transition (EMT) and, in turn, may increase migratory capabilities.
Overexpression of PFN2 in CRC cell lines with a low level of endogenous PFN2
inhibited the EMT process, as well as the associated migration; in addition,
myosin light chain (MLC) phosphorylation was upregulated. Inhibition of MLC
phosphorylation attenuated the inhibition of EMT and cell migratory abilities
induced by PFN2 overexpression in CRC cell lines, the results suggested that PFN2
may suppress cancer EMT and the subsequent metastasis by regulating cytoskeletal
reorganization. These results demonstrated that PFN2 may serve a suppressive role
in the metastasis of CRC and therefore may provide a new potential target for
cancer therapeutics.
free
free
free
